Sodium oligomannate, a seaweed-derived sugar mixture developed in China as an oral medication for Alzheimer's disease, acts mainly in the gut. One large trial showed modest, unconfirmed gains in memory and thinking scores; an earlier trial missed its main goal, and nearly all data come from the manufacturer. No human data exist for healthy brain aging. Side effects resembled placebo apart from raised blood fats. Legitimate supply is currently unavailable. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | <100 mg/dL | Phase 3 lipid signal |
| Triglycerides | <100 mg/dL | Phase 3 lipid signal |
| Fasting glucose / HbA1c | 75–90 mg/dL / <5.4% | Metabolic baseline |
| eGFR | >90 mL/min/1.73 m² | Renal clearance of drug |
| ALT | <25 U/L | Liver safety |
| hs-CRP | <1.0 mg/L | Systemic inflammation |
| Plasma p-tau217 | No established functional target; assay's validated cut-off | Confirms Alzheimer's pathology |
| MoCA | No established target in diagnosed disease; change from own baseline | Tracks cognitive response |
| Resting heart rate | Baseline reference point | Safety reference point |
Cadence: Baseline before starting; labs at 12 weeks, 24 weeks, then every 6 months; cognitive testing at 12 weeks and every 6 months; p-tau217 at baseline only